The purpose of this research study is to evaluate the effectiveness of using a combination of
pembrolizumab and olaparib when given before and after standard chemoradiation therapy in
treating locally advanced head and neck squamous cell carcinoma. Pembrolizumab and olaparib
are drugs that are approved for head and neck cancer treatment. However, FDA has not approved
the use of these two drugs together in treating head and neck cancer.